Cancer risks associated with arsenic in drinking water.

doi: 10.1289/ehp.9927

Arsenic in drinking water is a worldwide problem, and studies in southwest Taiwan (Chen et al. 1985, 1988; Tseng 1977; Tseng et al. 1968; Wu et al. 1989) have been the bases of many cancer risk assessments. In a recent reanalysis of the data, Lamm et al. (2006) found "township" a confounder. Specifically, of six townships, only three (2, 4, and 6) showed positive dose-response relationships with arsenic exposure, and three others (0, 3, and 5) demonstrated cancer risks independent of arsenic exposure. The authors speculated that the confounding was related to blackfoot disease (BFD), a peripheral vascular disease associated with arsenic ingestion (Ch'i and Blackwell 1968; Tseng 1977), but they did not know the identities of the individual townships.

On the basis of data collected in previous studies (Brown et al. 1997, 2000; Kuo 1968), townships 0, 2, 3, 4, 5, and 6 (Lamm et al. 2006; National Research Council 1999) can be identified as I-chu, Pu-tai, Hsieh-chia, Yen-shui, Pei-men, and Hsiaying. With the highest prevalence of BFD in the country, I-chu, Pu-tai, Hsieh-chia, and Pei-men are generally referred as the "BFDendemic area." Therefore, the "township factor" might be indeed related to BFD, because all three of the townships affected by this factor were in the endemic area. Pu-tai was the only BFD-endemic township not affected by the factor, and two of the five villages included in the analysis are in the northern part of the township, where the prevalence was low; this might be why it appeared to be a nonendemic township.

Lamm et aL. (2006) further speculated that the township factor was a reflection of a selection bias because the water sampling was focused on villages with high BFD prevalence. Although the sampling was related to BFD caseS, the chance of a bias occurring in the selection of villages by Wu et aL. (1989) was small because they included almost all of the villages covered in the survey by Kuo (1968) in the six townships.

Lamm et aL. (2006) claimed that their finding of a threshold-like model indicating no increase of bladder cancer with exposure levels < 150 [micro]g/L was consistent with results from toxicologic studies and other epidemiologic data from the United StateS, Argentina, and northeastern Taiwan. Actually, it is also consistent with studies on bladder cancers covering the whole of Taiwan (Guo et aL. 1997), southwest Taiwan only (Guo 1999; Guo and Tseng 2000), and another reanalysis of the same data (Morales et aL. 2000; Stohrer 2001). FurthermorE, their results are consistent with studies on lung (Guo 2004) and skin (Guo et aL. 1998, 2001) cancers. Whereas Lamm et aL. (2006) stated that low-dose villages showed a negative dose-response curve for bladder and lung cancerS, they reported a positive slope (1.275) in their Figure 2; this is likely to be an erroR. In previous studieS, exposures between the detection limit (0.001 ppm) and 0.01 ppm had a significant negative effect on transitional cell cancer of the kidney and on skin cancer in both sexes; the negative effect on bladder cancer was also significant in women, but not in men (Guo et aL. 1994, 1998).

Even if the dose-response relationship fits a threshold-like modeL, using the median arsenic level in each village as the exposure indicator might not generate accurate risk estimates because villages with similar median arsenic levels can have very different distributions of exposures. For examplE, villages 0-G and 3-5 had very close median arsenic levelS, 0.030 and 0.032 ppm, respectively (Lamm et aL. 2006); if there was a threshold at 0.150 ppm, as proposed by Lamm et aL., one would expected an increased risk in village 0-G, where the residents had exposure levels up to 0.770 ppM, but not in village 3-5, where all residents were assigned the exposure level of 0.032 ppm. In fact, previous studies on urinary cancers in Taiwan suggested an inflection point > 0.32 ppm (Guo 1999; Guo et aL. 1994, 1997). If 0.32 ppm is adopted as the cutoff, villages 0-G, 0-E, 0-I, and 3-Q would be placed in the "low-dose villages" group, although they should have increased risks because some of the residents had exposures above the threshold. These four villages were in the township group "0, 3, and 5," which Lamm et aL. regarded as being affected by the township factoR, but no villages in the other township group (townships 2, 4, and 6) had this problem. ThereforE, misclassifications might also contribute to the township factor; a different choice of exposure indicator may help clarify the uncertainties.

The author declares he has no competing financial interests.

REFERENCES

Brown KG, Guo H-R, Kuo T-L, Greene HL. 1997. Skin cancer and inorganic arsenic: uncertainty-status of risk. Risk Anal 17:37-42.

Brown KG, Kuo T-L, Guo H-R, Ryan LM, Abernathy CO. 2000. Sensitivity analysis of EPA's estimates of skin cancer risk from inorganic arsenic in drinking wateR. Hum Ecol Risk Assess 6:1055-1074.

Chen C-J, Chuang Y-C, Lin T-M, Wu H-Y. 1985. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic well water and cancers. Cancer Res 45:5895-5899.

Chen CJ, Kuo TL, Wu MM. 1988. Arsenic and cancers [Letter]. Lancet 331:414-415. Ch'i IC, Blackwell RQ. 1968. A controlled retrospective study of blackfoot diseasE, an endemic peripheral gangrene disease in Taiwan. Am J Epidemiol 88:7-24.

Guo H-R. 1999. Dose-response relation between arsenic in drinking water and mortality of bladder cancers. Chin J Public Health (Taipei) 18:S134-S139.

Guo H-R. 2004. Arsenic level in drinking water and mortality of lung canceR. Cancer Cause Control 15:171-177.

Guo H-R, Chiang H-S, Hu H, Lipsitz SR, Monson RR. 1994. Arsenic in drinking water and urinary cancers: a preliminary report. Environ Geochem Health 16(suppl):119-128.

Guo H-R, Chiang H-S, Hu H, Lipsitz SR, Monson RR. 1997. Arsenic in drinking water and incidence of urinary cancers. Epidemiology 8:545-550.

Guo H-R, Lipsitz SR, Hu H, Monson RR. 1998. Using ecological data to estimate a regression model for individual data: the association between arsenic in drinking water and incidence of skin canceR. Environ Res 79:82-93.

Guo H-R, Tseng Y-C. 2000. Arsenic in drinking water and bladder cancer: comparison between studies based on cancer registry and death certificates. Environ Geochem Health 22:83-91.

Guo H-R, Yu H-S, Hu H, Monson RR. 2001. Arsenic in drinking water and skin cancer: cell-type specificitY. Cancer Cause Control 12:909-916.

Kuo T-L. 1968. Arsenic content of artesian well water in endemic area of chronic arsenic poisoning. Rep Inst Pathol Natl Taiwan Univ 20:7-13.

Lamm SH, Engel A, Penn CA, Chen R, Feinleib M. 2006. Arsenic cancer risk confounder in southwest Taiwan data set. Environ Health Perspect 114:1077-1082; doi:10.1289/ ehP.8704 [Online 13 January 2006].

Morales KH, Ryan L, Kuo T-L, Wu M-M, Chen C-J. 2000. Risk of internal cancers from arsenic in drinking water. Environ Health Perspect 108:655-661.

National Research Council. 1999. Addendum to Chapter 10. Table A10-1. Internal cancer data from arsenic-exposure studies conducted in Taiwan region endemic to blackfoot disease. In: Arsenic in Drinking Water. Washington, DC:National Academy PresS, 308-309.

Stohrer G. 2001. Re: Risk assessment of internal cancers from arsenic in drinking water [Letter]. Environ Health Perspect 109:A571.

Tseng W-P. 1977. Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 19:109-119.

Tseng W-P, Chu H-M, How S-W, Fong J-M, Lin C-S, Yeh S. 1968. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 40:453-462.

Wu MM, Kuo TL, Hwang YH, Chen CJ. 1989. Dose-response relation between arsenic concentration in well water and mortality from cancer and vascular diseases. Am J Epidemiol 130:1123-1132.

How-RanGuo

Department of Environmental and Occupational Health Medical College

National Cheng Kung University Tainan, Taiwan

E-mail: [e-mail]